Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4K2OF
|
|||
| Drug Name |
ET140202
|
|||
| Drug Type |
CAR-T cell therapy
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1 | [1] | |
| Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 1 | [2] | ||
| Company |
Eureka Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-fetoprotein (AFP) | Target Info | . | [2] |
| KEGG Pathway | Hippo signaling pathway | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| FOXA2 and FOXA3 transcription factor networks | ||||
| Glucocorticoid receptor regulatory network | ||||
| Direct p53 effectors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03998033) An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140202 T Cells and Determine the Recommended Phase II Dose ("RP2D") in Adults With Advanced Hepatocellular Carcinoma ("HCC"). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03965546) Clinical Study of ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Advanced Liver Cancer. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.